30/60
2.5 / 5 stars
All 60 Win/Lose results and 60 gray no-data contests shown below
CUE Roast Me summary
Cue Biopharma, Inc. (CUE). Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth No data.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth No data.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth No data.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth No data.
Trailing 1 year (4 quarters): 4 wins, 4 losses, 4 no dataLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/2 |
WinCUE / S&P 357.39% / 15.20% |
WinCUE / S&P 354.37% / 15.00% |
No dataCUE / S&P / 50.40% |
| 2026-Q11/2 |
LoseCUE / S&P -24.59% / -4.33% |
WinCUE / S&P 309.60% / 11.30% |
No dataCUE / S&P / 27.70% |
| 2025-Q41/2 |
LoseCUE / S&P -57.58% / 2.65% |
WinCUE / S&P 195.75% / 9.00% |
No dataCUE / S&P / 13.40% |
| 2025-Q30/2 |
LoseCUE / S&P 5.43% / 8.12% |
LoseCUE / S&P -25.51% / 4.61% |
No dataCUE / S&P / 13.45% |
| 2025-Q20/2 |
LoseCUE / S&P -25.14% / 10.94% |
LoseCUE / S&P -0.11% / 4.83% |
No dataCUE / S&P / 10.63% |
| 2025-Q11/2 |
LoseCUE / S&P -16.42% / -4.27% |
WinCUE / S&P 13.83% / 4.98% |
No dataCUE / S&P / 10.57% |
| 2024-Q42/2 |
WinCUE / S&P 43.99% / 2.41% |
WinCUE / S&P 69.16% / 5.25% |
No dataCUE / S&P / 6.15% |
| 2024-Q31/2 |
LoseCUE / S&P -38.95% / 5.89% |
WinCUE / S&P 149.53% / 5.89% |
No dataCUE / S&P / 6.11% |
| 2024-Q21/2 |
LoseCUE / S&P -34.39% / 4.28% |
WinCUE / S&P 363.98% / 5.38% |
No dataCUE / S&P / 5.12% |
| 2024-Q11/2 |
LoseCUE / S&P -28.41% / 10.56% |
WinCUE / S&P 1525.00% / 5.71% |
No dataCUE / S&P / 5.59% |
| 2023-Q42/2 |
WinCUE / S&P 14.78% / 11.69% |
WinCUE / S&P 340.96% / 6.81% |
No dataCUE / S&P / 7.78% |
| 2023-Q30/2 |
LoseCUE / S&P -36.99% / -3.27% |
LoseCUE / S&P -59.14% / 7.52% |
No dataCUE / S&P / -5.03% |
| 2023-Q20/2 |
LoseCUE / S&P 2.24% / 8.74% |
LoseCUE / S&P -84.69% / 9.50% |
No dataCUE / S&P / -8.57% |
| 2023-Q11/2 |
WinCUE / S&P 25.26% / 7.50% |
LoseCUE / S&P -97.00% / 10.77% |
No dataCUE / S&P / -15.69% |
| 2022-Q41/2 |
WinCUE / S&P 27.80% / 7.56% |
LoseCUE / S&P -91.67% / 11.88% |
No dataCUE / S&P / -17.99% |
| 2022-Q31/2 |
LoseCUE / S&P -10.44% / -4.88% |
WinCUE / S&P 30.52% / 13.47% |
No dataCUE / S&P / -1.41% |
| 2022-Q21/2 |
LoseCUE / S&P -48.98% / -16.10% |
WinCUE / S&P 113.39% / 13.71% |
No dataCUE / S&P / 11.04% |
| 2022-Q11/2 |
LoseCUE / S&P -56.85% / -4.60% |
WinCUE / S&P 277.91% / 15.97% |
No dataCUE / S&P / 42.23% |
| 2021-Q41/2 |
LoseCUE / S&P -22.37% / 11.03% |
WinCUE / S&P 373.68% / 15.00% |
No dataCUE / S&P / 96.40% |
| 2021-Q32/2 |
WinCUE / S&P 25.06% / 0.58% |
WinCUE / S&P 92.11% / 10.77% |
No dataCUE / S&P / 69.42% |
| 2021-Q21/2 |
LoseCUE / S&P -4.51% / 8.55% |
WinCUE / S&P 36.50% / 6.58% |
No dataCUE / S&P / 51.81% |
| 2021-Q10/2 |
LoseCUE / S&P -2.48% / 6.17% |
LoseCUE / S&P -4.54% / -1.06% |
No dataCUE / S&P / 7.39% |
| 2020-Q40/2 |
LoseCUE / S&P -16.88% / 12.15% |
LoseCUE / S&P -8.79% / -3.72% |
No dataCUE / S&P / -33.42% |
| 2020-Q31/2 |
LoseCUE / S&P -38.60% / 8.93% |
WinCUE / S&P 36.09% / -2.04% |
No dataCUE / S&P / -27.10% |
| 2020-Q22/2 |
WinCUE / S&P 72.73% / 20.54% |
WinCUE / S&P 81.82% / -0.46% |
No dataCUE / S&P / -27.11% |
| 2020-Q12/2 |
WinCUE / S&P -10.61% / -19.60% |
WinCUE / S&P 201.78% / 3.47% |
No dataCUE / S&P / -14.75% |
| 2019-Q42/2 |
WinCUE / S&P 88.32% / 9.07% |
WinCUE / S&P 202.67% / 5.36% |
No dataCUE / S&P / 2.99% |
| 2019-Q30/1 |
LoseCUE / S&P -6.23% / 1.70% |
No dataCUE / S&P / 5.02% |
No dataCUE / S&P / 0.21% |
| 2019-Q21/1 |
WinCUE / S&P 16.30% / 4.30% |
No dataCUE / S&P / 6.64% |
No dataCUE / S&P / 8.65% |
| 2019-Q11/1 |
WinCUE / S&P 64.47% / 13.65% |
No dataCUE / S&P / 8.12% |
No dataCUE / S&P / 14.29% |
| 2018-Q40/1 |
LoseCUE / S&P -48.07% / -13.52% |
No dataCUE / S&P / 9.05% |
No dataCUE / S&P / 18.23% |
| 2018-Q30/1 |
LoseCUE / S&P -23.69% / 7.71% |
No dataCUE / S&P / 10.21% |
No dataCUE / S&P / 19.06% |
| 2018-Q20/1 |
LoseCUE / S&P -15.59% / 3.43% |
No dataCUE / S&P / 9.03% |
No dataCUE / S&P / 14.46% |
| 2018-Q10/0 |
No dataCUE / S&P / -0.76% |
No dataCUE / S&P / 7.68% |
No dataCUE / S&P / 12.46% |
| 2017-Q40/0 |
No dataCUE / S&P / 6.64% |
No dataCUE / S&P / 7.03% |
No dataCUE / S&P / 13.82% |
| 2017-Q30/0 |
No dataCUE / S&P / 4.48% |
No dataCUE / S&P / 5.68% |
No dataCUE / S&P / 17.57% |
| 2017-Q20/0 |
No dataCUE / S&P / 3.09% |
No dataCUE / S&P / 4.83% |
No dataCUE / S&P / 17.74% |
| 2017-Q10/0 |
No dataCUE / S&P / 6.07% |
No dataCUE / S&P / 3.67% |
No dataCUE / S&P / 13.32% |
| 2016-Q40/0 |
No dataCUE / S&P / 3.82% |
No dataCUE / S&P / 2.09% |
No dataCUE / S&P / 7.05% |
| 2016-Q30/0 |
No dataCUE / S&P / 3.85% |
No dataCUE / S&P / 0.20% |
No dataCUE / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | CUE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 19.96% | 20.78% |
| Annualized return | 19.96% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | CUE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -92.20% | 83.14% |
| Annualized return | -39.97% | 12.86% |
10Y · 2018-01-02 to 2026-08-28
| Metric | CUE total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -91.95% | 319.30% |
| Annualized return | -22.28% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |